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Abstract
Purpose Hepatitis B viral markers may be useful for
predicting outcomes such as liver-related deaths or devel-
opment of hepatocellular carcinoma. We determined the
frequency of these markers in different clinical stages of
chronic hepatitis B infection.
Methods We compared baseline hepatitis B viral mark-
ers in 317 patients who were enrolled in a prospective
study and identiﬁed the frequency of these tests in immune-
tolerant (IT) patients, in inactive carriers, and in patients
with either hepatitis B e antigen (HBeAg)-positive or
HBeAg-negative chronic hepatitis or cirrhosis.
Results IT patients were youngest (median age 27 years)
and HBeAg-negative patients with cirrhosis were oldest
(median age 58 years) (p = 0.03 to\0.0001). The male to
female ratio was similar both in IT patients and in inactive
carriers, but there was a male preponderance both in
patients with chronic hepatitis and in patients with cirrhosis
(p\0.0001). The A1896 precore mutants were most pre-
valent in inactive carriers (36.4%) and HBeAg-negative
patients with chronic hepatitis (38.8%; p\0.0001), and
the T1762/A1764 basal core promoter mutants were most
often detected in HBeAg-negative patients with cirrhosis
(65.1%; p = 0.02). Genotype A was detected only in 5.3%
of IT patients, and genotype B was least often detected in
both HBeAg-Positive patients with chronic hepatitis and
cirrhosis (p = 0.03). The hepatitis B viral DNA levels were
lowest in inactive carriers (2.69 log10 IU/mL) and highest
in IT patients (6.80 log10 IU/mL; p = 0.02 to\0.0001). At
follow-up, HBeAg-positive and HBeAg-negative patients
with cirrhosis accounted for 57 of 64 (89.1%) liver-related
deaths (p\0.0001).
Conclusion Differences in baseline hepatitis B viral
markers were detected in patients in various clinical stages
of hepatitis B virus infection. HBeAg-positive and HBeAg-
negative patients with cirrhosis accounted for the majority
of the liver-related fatalities.
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Introduction
Patients with chronic hepatitis (CH) B have different clin-
ical presentations. On initial evaluation in the clinic, routine
liver, hematologic, and virologic tests are obtained and a
liver biopsy may be required for diagnosis. Thereafter,
patients may be placed into one of several clinical catego-
ries. Those with chronic hepatitis will have elevated serum
aminotransferase levels and liver biopsy ﬁndings that show
grade 1–3 inﬂammation and stage 1–3 ﬁbrosis, whereas
patients with cirrhosis may have clinical evidence of
chronic liver disease, decreased platelet counts, and histo-
logic ﬁndings of grade 4 inﬂammation and stage 4 ﬁbrosis
[1]. More difﬁcult to categorize are hepatitis B surface
antigen (HBsAg)-positive patients who are asymptomatic,
have normal liver tests, and whose liver biopsy results may
not be available to assist with diagnosis. In these patients,
those who are hepatitis B e antigen (HBeAg) negative with
low or undetectable levels of hepatitis B viral DNA (HBV
DNA) are considered inactive carriers, whereas others who
are HBeAg positive with high levels of HBV DNA are
categorized as ‘‘immune tolerant (IT) [2]. In a clinical set-
ting, these latter patients are virologic ‘‘active’’ carriers
since histologic ﬁndings show little or no ﬁbrosis [3].
Recently, the availability of other hepatitis B viral
markers has shed further light on their potential roles in
identifying patients who develop liver complications. The
presence of high levels of HBV DNA has been associated
with progression to cirrhosis and to the development of
hepatocellular carcinoma (HCC) [4, 5]. Also, hepatitis B
virus(HBV)genotypeCandspeciﬁcallelesofthebasalcore
promoter (BCP) and precore (PC) genes were associated
with a high risk of developing HCC [6]. The T1762/A1764
BCP mutants have been associated with progressive liver
disease, hepatic decompensation, and HCC [7–9]. The role
of A1896 PC mutants is less clear since reports from Asia
showed that there was no difference in its prevalence in
patientswithorwithoutlivercomplications,anditsselection
mayactuallyleadtotheinactivationofongoingliverdisease
[8,9].However,reportsfromEuropeshowedthattheA1896
PC mutants were associated with an aggressive form of
HBeAg-negative chronic hepatitis [10, 11].
A recent report from the Agency for Healthcare
Research and Quality on management of CHB suggested
that patients in different clinical stages of CHB needed to
be more clearly deﬁned, since antiviral treatment guides for
hepatitis B are based on speciﬁc categories of patients [12].
Accordingly, the report herein describes differences in the
baseline laboratory tests and HBV viral markers of patients
in different clinical stages of CHB. These observations may
be useful in identifying patients who will have liver disease
progression and therefore be the main targets for antiviral
therapy.
Methods
Patients
FromJanuary1989toMarch1998,HBsAg-positivepatients
who presented at our clinic in Pasadena, CA, were enrolled
in a prospective follow-up study [1]. Patients who were
positiveforanti-HCV or HIV, orhada history ofalcoholism
or other chronic liver diseases such as hemochromatosis and
autoimmune hepatitis, were excluded. During the ﬁrst visit,
routine liver and hematologic tests and HBeAg serocon-
version rates were obtained. Serum was collected from each
patient, stored at -70C, and later tested for HBV DNA,
BCP mutants, PC mutants, and HBV genotypes in one
research laboratory [7]. For the present analysis, HBsAg-
positive patients were stratiﬁed into six clinical categories:
(1) immune tolerant, (2) inactive carriers, (3) HBeAg-posi-
tivechronichepatitis,(4)HBeAg-negativechronichepatitis,
(5) HBeAg-positive cirrhosis, and (6) HBeAg-negative cir-
rhosis. By deﬁnition, IT patients were HBeAg positive, had
normal alanine aminotransferase (ALT) levels, and had
HBV DNA values of more than 20,000 IU/mL, whereas
inactive carriers were HBeAg negative, had normal ALT
values, and their HBV DNA levels were 20,000 IU/mL or
less[13,14].Atbaseline,patientsinthelattertwocategories
were asymptomatic, and liver biopsies were not requested.
One hundred forty-four HBsAg-positive patients had ele-
vated serum aminotransferase levels, and all had liver
biopsies (grades 1–3 and stages 1–3), conﬁrming the diag-
nosis of chronic hepatitis. One hundred thirty patients had
abnormallivertestsandhadclinicalstigmataofchronicliver
disease [15]. Liver biopsies were obtainedfrom 109 of these
patients, which showed the presence of cirrhosis. The
remaining21patientshadplateletcountsbelow75,000 mm
3
and liver biopsies were not performed because of the risk of
bleeding.Thesubsequentclinicaloutcomesinthesepatients
have been reported [1].
Statistical analysis
The baseline data were descriptively summarized and the
assessment of differences was completed using the analysis
of variance with post hoc pairwise Student t tests for
parametric data. Categorical data were summarized using
frequencies and analyzed by Chi-squared analyses for the
assessment of differences. All statistical signiﬁcance values
were assessed at p\0.05.
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Baseline characteristics
The median age of the 317 HBsAg-positive patients was
49 (6, 80) years, 76% were men and 76% were Asian
(Table 1). One hundred eighty-one (57%) patients were
HBeAg positive, 53% had genotype C, 28% had A1896 PC
mutants, and 45% had T1762/A1764 BCP mutants. The
median HBV DNA level was 5.2 (0, 9.2) log10 IU/mL.
Baselines characteristics and laboratory tests by clinical
status
Compared with others, IT patients were signiﬁcantly
younger in age, and HBeAg-negative patients with cir-
rhosis were older in age (p = 0.03 to \0.0001; Table 2).
The male to female ratios were similar in the IT patients
and inactive carriers, but there was an increase in male
preponderance in the chronic hepatitis and cirrhosis groups
(p\0.0001; Table 3). Compared with others, the HBeAg-
positive and HBeAg-negative patients with cirrhosis had
the lowest albumin values and platelet counts (p = 0.04 to
\0.0001).
Virologic tests by clinical status
Compared with others, IT patients had the highest median
HBV DNA levels (6.81 log10 IU/mL, p = 0.02 to
\0.0001), and inactive carriers had the lowest HBV DNA
values (2.96 log10 IU/ml, p = 0.02 to\0.0001) compared
with other groups (Table 2). Genotype A was least often
detected in IT patients, and genotype B was least often
detected in both HBeAg-positive patients with chronic
hepatitis and cirrhosis (p = 0.03; Table 3). The A1896 PC
mutants were more frequently detected in inactive carriers
(36.4%) and in HBeAg-negative patients with chronic
hepatitis (38.8%, p\0.0001). The T1762/A1764 BCP
mutants were most often detected in HBeAg-negative
patients with cirrhosis (65.1%, p = 0.02). A scheme on the
progression of CHB, which includes our ﬁndings in each
clinical category, is shown in Fig. 1.
Liver-related deaths
During a mean follow-up of 84 months, 30 developed HCC
and 37 died from non-HCC liver-related complications [1].
Most deaths (89%) occurred in the HBeAg-positive and
HBeAg-negative patients with cirrhosis (p\0.0001;
Table 4).
Discussion
The natural history of CHB consists of four phases [2]. The
ﬁrst is the immune tolerance phase, which is mainly
observed in younger patients who acquire HBV infection
either at birth from HBsAg-positive mothers or by expo-
sure during early childhood. These individuals have no
symptoms, liver tests are normal, HBeAg is positive, and
high circulating levels of HBV DNA ([20,000 IU/mL) are
observed. The second is the immune clearance phase,
which occurs in the second or third decade of life during
which time patients are still HBeAg positive and have high
HBV DNA levels, but the serum ALT levels are elevated.
In this phase, liver biopsy ﬁndings show active inﬂamma-
tion and ﬁbrosis. There are three potential sequelae to the
second phase. Patients may either (1) remain HBeAg
positive with future episodes of HBV reactivation, (2)
undergo seroconversion to hepatitis B e antibody (anti-
HBe) positivity and enter into the IC phase, or (3) progress
to HBeAg-negative chronic hepatitis. Phase 3 is the IC
phase characterized by anti-HBe positivity, normal ALT
values, and low or undetectable serum HBV DNA levels.
Phase 4 is reactivation of HBV after HBeAg seroconver-
sion and is referred to as HBeAg-negative chronic hepati-
tis. In this phase, ALT levels are elevated, HBV DNA
levels are high, and histologic features on liver biopsy
Table 1 Baseline characteristics of 317 HBsAg-positive patients
Age (years)
a 49 (6, 80)
Males 240 (76%)
Asians 240 (76%)
Albumin (g/dL)
a 4.2 (1.9, 5.1)
Bilirubin (mg/dL)
a 0.7 (0.1, 3.9)
AST (U/L)
a 43 (8, 980)
ALT (U/L)
a 50 (1, 620)
Platelets (910
3 mm
3)
a 188 (34, 527)
HBeAg
? 181 (57%)
- 136 (43%)
Genotype (273)
b
A 49 (18%)
B 73 (27%)
C 145 (53%)
Mixed 6 (2%)
Precore (311)
b
A1896 mutant 88 (28%)
Wild 223 (72%)
Basal core promoter (246)
b
T1762/A1764 mutant 110 (45%)
Wild 136 (55%)
HBV DNA (log10 IU/mL)
a 5.2 (0, 9.2)
a Median (minimal, maximal)
b Number detectable in 317 patients
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123show progressive inﬂammation and ﬁbrosis. Although of
value for understanding the natural history of hepatitis B,
the four phases are neither helpful in identifying the clin-
ical stages of patients presenting to the physician with CHB
nor useful when evaluating patients for potential antiviral
therapy.
There are few studies identifying prognostic baseline
characteristics in patients in the four phases of CHB
infection, but reports are available on the prevalence of
hepatitis B viral markers in various clinical settings of
CHB. A recent study from Hong Kong described the course
of 57 patients considered to be in the IT phase of CHB [3].
By deﬁnition, all patients were HBeAg positive, 32 had
genotype B and 25 had genotype C, and the mean HBV
was 9.1 log10 IU/mL. Liver biopsy ﬁndings showed that 19
had ﬁbrosis stage 0 and 38 had ﬁbrosis stage 1. A report
from Taiwan showed that 71% of asymptomatic carriers
were genotype B compared with 15–23% with genotype C
[9, 16]. Genotype C was associated with lower rates of
HBeAg seroconversion, which occurred at an older age,
and these patients were more likely to have worse clinical
outcomes than genotype B patients [17, 18]. Also,
Table 2 Bivariate analysis of continuous variables in 317 HBsAg-positive patients
Immune-tolerant
HBeAg? (no. 19)
Inactive carrier
HBeAg- (no. 24)
Chronic hepatitis Cirrhosis p value
HBeAg?
(no. 93)
HBeAg-
(no. 51)
HBeAg?
(no. 69)
HBeAg-
(no. 61)
Age (years) 27 (9, 63) 45 (16, 64) 44 (6, 77) 49 (16, 75) 54 (22, 78) 58 (28, 80) 0.03 to\0.0001
Albumin (mg/dL) 4.4 (3.5, 4.8) 4.4 (2.8, 5) 4.3 (1.9, 5) 4.4 (3.4, 4.9) 3.9 (2.2, 5.1) 3.9 (1.9, 5) \0.0001
Bilirubin (mg/dL) 0.5 (0.2, 1.4) 0.6 (0.1, 1) 0.6 (0.1, 3.2) 0.6 (0.3, 1.4) 0.8 (0.2, 2.8) 1.0 (0.3, 3.9) 0.46
ALT (U/L) 27 (1, 45) 23 (2, 45) 58 (2, 436) 45 (1, 98) 67 (1, 500) 52 (9, 620) 0.05 to\0.000
AST (U/L) 28 (11, 45) 21.5 (15,45) 43 (8, 239) 39 (12, 126) 55 (18, 270) 51 (15, 980) 0.04–0.001
Platelets
(910
3 mm
3)
268 (160, 527) 200 (103, 334) 202 (87, 376) 205 (79, 314) 140 (34, 336) 113 (44, 311) 0.0002 to\0.0001
HBV DNA
(log10 IU/mL)
6.81 (4.31, 8.49) 2.69 (0, 4.26) 5.55 (0, 8.97) 4.98 (0, 9.02) 4.91 (0, 9.20) 5.51 (0, 8.97) 0.02 to\0.0001
Values represent median (minimal, maximal)
ALT alanine aminotransferase, AST aspartate aminotransferase
Table 3 Bivariate analysis of discrete variables in HBsAg-positive patients
Immune-tolerant
HBeAg? (no. 19)
Inactive carrier
HBeAg- (no. 24)
Chronic hepatitis Cirrhosis p value
HBeAg?
(no. 93)
HBeAg-
(no. 51)
HBeAg?
(no. 69)
HBeAg-
(no. 61)
Sex \0.0001
Male 9 (47.4%) 12 (50%) 75 (80.7%) 33 (64.7%) 56 (81.2%) 55 (90.2%)
Female 10 (52.6%) 12 (50%) 18 (19.3%) 18 (39.3%) 13 (18.8%) 6 (9.8%)
Race 0.007
Asian 18 (94.7%) 18 (75%) 73 (78.5%) 40 (78.4%) 41 (59.4%) 50 (82%)
Non-Asian 1 (5.3%) 6 (25%) 20 (21.5%) 11 (21.6%) 28 (40.6%) 11 (18%)
Genotype (no. 273) 0.03
A 1 (5.3%) 3 (18.7%) 19 (21.6%) 5 (12.8%) 16 (26.2%) 5 (10%)
B 7 (36.8%) 6 (37.5%) 17 (19.3%) 15 (38.5%) 8 (13.1%) 20 (40%)
C 11 (57.9%) 7 (43.7%) 50 (56.8%) 19 (48.7%) 34 (55.7%) 24 (48%)
Mixed 0 0 2 (2.3%) 0 3 (4.9%) 1 (2%)
Precore (no. 311) \0.0001
A1896 mutant 4 (21%) 8 (36.4%) 11 (11.8%) 19 (38.8%) 17 (24.6%) 29 (29.1%)
Wild 15 (79%) 14 (63.6%) 82 (88.2%) 30 (61.2%) 52 (75.4%) 30 (50.8%)
Basal core promoter (no. 246) 0.02
T1762/A1764 mutant 7 (43.7%) 6 (54.5%) 26 (32.1%) 16 (44.4%) 27 (45.8%) 28 (65.1%)
Wild 9 (56.2%) 5 (45.5%) 55 (67.9%) 20 (55.6%) 32 (54.2%) 15 (34.9%)
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than in asymptomatic carriers, and genotype B patients
were less apt to progress to cirrhosis [9]. In an 11-year
follow-up study from Taiwan, elevated HBV DNA levels
at baseline were associated with progression to cirrhosis
[5]. This was evident even in patients who were HBeAg
negative and had normal ALT levels at baseline. Another
report from China indicated that compared with HBV
carriers with low or undetectable viral loads, those with
high viral loads tended to have adverse clinical outcomes
[19]. Reports from Europe indicated that mutations in the
nucleotide 1896 and nucleotide 1762/1764 regions of the
hepatitis B core genome were associated with progressive
HBeAg-negative chronic hepatitis [11, 20]. Liver biopsy
ﬁndings in these latter patients showed that more than 5%
had moderate to severe inﬂammation and up to 40% had
cirrhosis [21, 22]. Also, the risk of cirrhosis was reported to
be higher in the HBeAg-negative patients with chronic
hepatitis than in the HBeAg-positive patients with chronic
hepatitis [23]. However, reports from Asia indicated that
acquisition of A1896 PC mutants may lead to inactive liver
disease and that similar percentages of A1896 PC muta-
tions were detected in asymptomatic carriers and patients
with cirrhosis and HCC [9, 24]. At present, the role of
A1896 PC mutants in the progression of liver disease
remains unclear. On the other hand, the T1762/A1764 BCP
mutants have been associated with liver disease
Immune Tolerant  Inactive Carrier 
HBeAg +  ALT  27 U/L  HBeAg -  ALT  22 U/L 
Age 27 yrs  M:F 1:1 Age 45 yrs  M:F 0.9:1
PCM 21% BCPM  44% PCM 36% BCPM 54%
HBV DNA: 6.81 log10 IU/ml  HBV DNA: 2.69 log10 IU/ml 
Chronic Hepatitis  Chronic Hepatitis 
HBeAg +  ALT  58 U/L  HBeAg -  ALT  45 U/L 
Age 44 yrs  M:F 4.2:1 Age 49 yrs  M:F 1.8:1
PCM 12% BCPM  32% PCM 39% BCPM 44%
HBV DNA: 5.55 log10 IU/ml  HBV DNA: 4.98 log10 IU/ml 
Cirrhosis Cirrhosis 
HBeAg +  ALT  67 U/L  HBeAg -  ALT  52 U/L 
Age 54 yrs  M:F 4.3:1 Age 58 yrs  M:F 9.2:1
PCM 25% BCPM  46% PCM 29% BCPM 65%
HBV DNA: 4.91 log10 IU/ml  HBV DNA: 5.51 log10 IU/ml 
Fig. 1 A scheme on the
progression of chronic hepatitis
B infection. ALT, age and HBV
DNA expressed as medians;
HBV DNA in log10 IU/mL;
ALT alanine aminotransferase,
PCM precore mutant, BCPM
basal core promoter mutant
Table 4 Liver-related deaths in 317 patients with chronic hepatitis B
No. of deaths from
liver-related
complications (%)
Immune tolerant (no. 19) 0
Inactive carriers (no. 24) 0
Chronic hepatitis
a
HBeAg? (no. 93) 5 (5.4%)
HBeAg- (no. 51) 2 (3.9%)
Cirrhosis
b
HBeAg? (No. 69)
c 29 (42%)
HBeAg- (No. 61)
d 28 (45.9%)
Total 64 (20.2%)
a All deaths from HCC
b HBeAg-positive and HBeAg-negative cirrhosis patients versus
others: p\0.0001
c Seven deaths from HCC; 22 deaths from non-HCC liver
complications
d 13 deaths from HCC; 15 deaths from non-HCC liver complications
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123progression, hepatic decompensation, and HCC develop-
ment [7–9].
In the report herein, we classiﬁed our patients into six
clinical categories. Age differences were noted, with IT
patients being the youngest and HBeAg-negative patients
with cirrhosis being the oldest. Gender differences were
also noted, with an equal male to female ratio in IT patients
and inactive carriers but a male preponderance in the
patients with chronic hepatitis and cirrhosis. The highest
HBV DNA levels were in the IT patients, and the lowest
levels in inactive carriers. There did not appear to be sig-
niﬁcant differences in A1896 PC mutations since patients
with cirrhosis had similar prevalence as IT patients and
inactive carriers. HBeAg-negative patients with cirrhosis
had the highest prevalence of T1762/A1764 BCP mutants,
but our HBeAg-positive patients with cirrhosis had a
similar prevalence of T1762/A1764 BCP mutants as IT
patients and inactive carriers. These ﬁndings indicate that
basal core mutants may appear in HBeAg-positive patients
and may be independent of HBeAg seroconversion. Further
investigations of hepatitis B viral markers in different
categories of patients with hepatitis B relating to their
eventual clinical outcomes are warranted.
There are several limitations to our study. Liver biopsies
were not obtained for 96 clinically asymptomatic HBsAg-
positive patients who had normal liver tests [1]. By deﬁ-
nition, 19 of these patients were classiﬁed as immune
tolerant since they were positive for HBeAg and their HBV
DNA levels were more than 20,000 IU/mL. Also, by def-
inition, 24 patients were classiﬁed as inactive carriers since
they were negative for HBeAg, had normal baseline ALT
levels, and their HBV DNA levels were equal to or less
than 20,000 IU/mL or undetectable. This level of HBV
DNA was chosen to identify patients with hepatitis B who
were inactive and nonprogressive since the lower limits of
detection for HBV DNA levels at that time period was
5 log10 IU/mL [13]. However, it has been recently reported
that 21–37% HBeAg-negative patients with persistently
normal ALT levels and HBV DNA levels of less than
5 log10 IU/mL may have liver biopsy ﬁndings of signiﬁ-
cant inﬂammation and ﬁbrosis [25, 26]. In addition, anti-
HBeAg-positive patients with HBV DNA levels of less
than 5 log10 IU/mL may still progress to cirrhosis, expe-
rience liver decompensation, and develop HCC [4, 5, 27,
28]. The level of HBV DNA that includes inactive carriers
may be less than 5 log10 IU/mL [29], but a cutoff level of
less than 4 log10 IU/mL may be more appropriate since
patients with HBV DNA levels above this value may still
develop liver-related complications [30]. In our inactive
carriers, the median HBV DNA level was 2.69 log10 IU/
mL. Also, serial measurements of ALT levels are necessary
to reafﬁrm the IC state if liver biopsies are not available
[14]. In our 24 inactive carriers, the serum ALT levels have
remained persistently normal over a 10-year period
(Fig. 2). In addition, there were 53 of the 96 remaining
patients who did not ﬁt into these 2 categories. Of these, 47
were HBeAg negative and had normal ALT and HBV
DNA levels of 8.0 log10 IU/mL. It is possible that these
patients were in the quiescent phase of HBeAg-negative
chronic hepatitis. The remaining six patients were HBeAg
positive, had normal ALT and HBV DNA levels of
2.3 log10 IU/mL, and they may have been in the process of
HBeAg seroconversion. Up to the present, none of the ‘‘no
ﬁt’’ patients have developed liver complication and are still
currently followed in our clinic. Another limitation is that
we analyzed only hepatitis B viral markers at baseline, and
it is possible that HBeAg seroconversion with subsequent
viral mutations as well as changes in HBV DNA levels
may have inﬂuenced the course of the disease.
In dividing our patients with hepatitis B into six clinical
categories, we were able to determine which categories of
patients eventually died from complications of hepatitis B
infection. Hepatitis B viral markers must be used in con-
junction with routine laboratory tests for clinical assess-
ment of patients and together the information will be useful
for the identiﬁcation of patients who will require close
monitoring and who will need antiviral therapy.
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